Drug Profile
Azelastine/mometasone - Hanlim Pharmaceutical
Alternative Names: Mometasone/azelastine; Nasaflex Nasal SprayLatest Information Update: 13 Feb 2019
Price :
$50
*
At a glance
- Originator Hanlim Pharmaceutical
- Class Anti-inflammatories; Antiallergics; Antiasthmatics; Glucocorticoids; Phthalazines; Pregnadienediols; Small molecules
- Mechanism of Action Glucocorticoid receptor agonists; Histamine H1 receptor antagonists; Mast cell stabilisers
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Perennial allergic rhinitis
Most Recent Events
- 13 Feb 2019 Chemical structure information added
- 10 Oct 2013 Registered and launched (prior to 10 October 2013) for Perennial allergic rhinitis in South Korea (Intranasal)
- 01 Nov 2012 Hanlim Pharmaceutical completes its phase III trial in Perennial allergic rhinitis in South Korea (NCT01470053)